Humacyte, Inc. (NASDAQ:HUMA) Stock Has Consensus Price Target of $4.48 According to Brokerages

Shares of Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) have received an average recommendation of “Moderate Buy” from the eight research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $4.48.

HUMA has been the subject of a number of recent research reports. Benchmark decreased their target price on Humacyte from $2.00 to $1.00 and set a “speculative buy” rating for the company in a research report on Thursday, August 13th. HC Wainwright reaffirmed a “buy” rating on shares of Humacyte in a research report on Friday, October 16th. Wall Street Zen upgraded Humacyte to a “sell” rating in a research note on Saturday, November 14th. Williams Trading set a $1.00 price target on Humacyte in a research note on Friday, October 16th. Finally, Cantor Fitzgerald set a $1.00 price objective on Humacyte in a report on Thursday, November 12th.

Check Out Our Latest Analysis on HUMA

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Alyeska Investment Group L.P. purchased a new position in shares of Humacyte in the second quarter worth about $4,700,000. BlackRock Inc. purchased a new position in Humacyte during the 2nd quarter valued at about $3,777,000. Marshall Wace LLP increased its holdings in Humacyte by 1,548.0% during the 3rd quarter. Marshall Wace LLP now owns 2,996,553 shares of the company’s stock valued at $1,558,000 after purchasing an additional 2,814,722 shares during the period. GSA Capital Partners LLP bought a new position in Humacyte during the 2nd quarter valued at approximately $785,000. Finally, Private Advisor Group LLC bought a new position in shares of Humacyte during the third quarter valued at approximately $491,000. 44.71% of the stock is currently owned by institutional investors.

Humacyte Stock Performance

NASDAQ HUMA opened at $0.45 on Thursday. The company has a fifty day moving average price of $0.49 and a 200-day moving average price of $0.77. The firm has a market cap of $123.62 million, a price-to-earnings ratio of -1.01 and a beta of 2.64. The company has a debt-to-equity ratio of 3.65, a current ratio of 3.34 and a quick ratio of 3.11. Humacyte has a 1 year low of $0.34 and a 1 year high of $1.52.

About Humacyte

(Get Free Report)

Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for vascular repair and other medical applications. Its technology uses human vascular cells to create vessels that are processed to remove the cells, leaving an acellular structure designed for implantation. The company’s lead product, Symvess, is an acellular tissue-engineered vessel for treating extremity arterial injuries in adults when a patient’s own vein cannot be used for surgical revascularization. The U.S. Food and Drug Administration approved Symvess in December 2024.

Further Reading

Analyst Recommendations for Humacyte (NASDAQ:HUMA)

Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.